Research Paper Volume 13, Issue 6 pp 8155—8176
FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma
Figure 9. The methylation of FAM72A/B/D in LUAD. (A–C) The visualization between the methylation level and the FAM72A/B/D expression; (D) The Kaplan-Meier survival of the promoter methylation of FAM72B.